# Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

> **NCT05795296** · PHASE2 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Fruquintinib
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT05795296
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2024-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05795296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05795296, "Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05795296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*